Bottom line
SWHFX vs ETHSX: the short answer
SWHFX (Schwab Health Care Fund) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 69% by weight.
SWHFX is cheaper at 0.8% vs 1.18% — a difference of $38 a year per $10,000 invested.
Over five years, SWHFX returned +6.5% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
SWHFX vs ETHSX side by side
| SWHFX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Schwab | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.8% | 1.18% |
| Annual cost per $10k | $80 | $118 |
| 10-yr cost on $10k (prospectus) | $990 | $1,911 |
| Max front load | — | 5.25% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +15.9% | −1.9% |
| 5-yr return (annualized) | +6.5% | +5.3% |
| 10-yr return (annualized) | +8.1% | +6.4% |
| Best quarter | +15.3% | +14.2% |
| Worst quarter | −12.1% | −12.1% |
| Net assets (fund) | $642.3M | $757.9M |
| Number of holdings | 80 | 42 |
| Portfolio turnover | 41% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SWHFX | ETHSX | Difference |
|---|---|---|---|
| 2024 | +0.1% | +3.5% | −3.4% |
| 2023 | +0.7% | +5.7% | −5.0% |
| 2022 | −4.7% | −9.4% | +4.8% |
| 2021 | +23.3% | +22.1% | +1.2% |
| 2020 | +12.9% | +13.0% | −0.2% |
| 2019 | +17.6% | +26.0% | −8.4% |
| 2018 | +4.0% | +6.0% | −2.0% |
| 2017 | +20.2% | +16.2% | +4.0% |
| 2016 | −4.4% | −14.9% | +10.5% |
Source: Fund prospectus bar charts
Holdings overlap
16 of SWHFX's top 25 holdings also appear in ETHSX's top 25.
| Holding | SWHFX | ETHSX |
|---|---|---|
| Eli Lilly & Co | 13.92% | 12.47% |
| Johnson & Johnson | 6.94% | 6.45% |
| AbbVie Inc | 5.81% | 6.46% |
| Merck & Co Inc | 4.98% | 5.08% |
| UnitedHealth Group Inc | 4.74% | 5.49% |
| Gilead Sciences Inc | 3.24% | 3.34% |
| Novartis AG | 2.92% | 1.65% |
| Bristol-Myers Squibb Co | 2.44% | 4.25% |
| Medtronic PLC | 2.29% | 1.80% |
| Roche Holding AG | 2.29% | 5.44% |
| Thermo Fisher Scientific Inc | 2.16% | 2.79% |
| Stryker Corp | 2.11% | 2.21% |
| Vertex Pharmaceuticals Inc | 1.89% | 3.38% |
| Boston Scientific Corp | 1.60% | 2.18% |
| Abbott Laboratories | 1.60% | 1.65% |
Source: SEC Form N-PORT
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between SWHFX and ETHSX?
Which is cheaper, SWHFX or ETHSX?
Should I own both SWHFX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.